Results 291 to 300 of about 9,130,139 (414)

Cognitive change in patients with Huntington disease on the Repeatable Battery for the Assessment of Neuropsychological Status [PDF]

, 2009
Leigh J. Beglinger, Karen Duff, Jessica Allison, Danielle Theriault, Justin J. F. O’Rourke, Anne Leserman, Jane S. Paulsen   +6 more
openalex   +1 more source

Experimental Parkinsonism induced by tetanus toxin injected into basal ganglia

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Local inhibitory circuits and long‐range inhibitory projections within the interconnected basal ganglia nuclei are critical for control of voluntary movement and pathophysiology of different extrapyramidal movement disorders.
Patrik Meglić, Petra Šoštarić, Davor Virag, Ana Knezović, Nikola Habek, Ornella Rossetto, Ivica Matak   +6 more
wiley   +1 more source

Intraneuronal polyglutamine aggregates are present in diverse CNS locations in Huntington disease

, 2007
Emily Herndon, Christa L. Hladik, Ping Shang, Dennis K. Burns, Charles L. White   +4 more
openalex   +1 more source

Neuroanatomic Profile of Polyglutamine Immunoreactivity in Huntington Disease Brains [PDF]

, 2009
Emily Herndon, Christa L. Hladik, Ping Shang, Dennis K. Burns, Jack Raisanen, Charles L. White   +5 more
openalex   +1 more source

Indigenous peoples and local community reports of climate change impacts on biodiversity

Conservation Biology, EarlyView.
Abstract Climate change impacts on biodiversity have been primarily studied through ecological research methods, largely ignoring other knowledge systems. Indigenous and local knowledge systems include rich observations of changes in biodiversity that can inform climate change adaptation planning and environmental stewardship.
Albert Cruz‐Gispert, David García‐del‐Amo, André B. Junqueira, Christoph Schunko, Santiago Álvarez‐Fernández, Victoria Reyes‐García   +5 more
wiley   +1 more source

Safety and Efficacy of Deutetrabenazine at High versus Lower Daily Dosages in the ARC-HD Study to Treat Chorea in Huntington Disease. [PDF]

CNS Drugs
Frank S, Testa CM, Goldstein J, Kayson E, Leavitt BR, Oakes D, O'Neill C, Whaley J, Gross N, Chaijale N, Barash S, Gordon MF, Huntington Study Group/ARC-HD Investigators and Coordinators.   +12 more
europepmc   +1 more source

The Application of Polymeric Nanoparticles as Drug Delivery Carriers to Cells in Neurodegenerative Diseases

Cell Proliferation, EarlyView.
Polymeric nanoparticles represent promising drug (gene) delivery carriers to the brain due to their unique advantages to facilitate the penetration of blood–brain barrier and endocytosis of neuronal cells in neurodegenerative diseases. ABSTRACT In spite of great advances in modern medicine, there are a few effective strategies for the treatment of ...
Lian Jin, Libo Nie, Yan Deng, Ghulam Jilany Khana, Nongyue He   +4 more
wiley   +1 more source

Integrative determination of atomic structure of mutant huntingtin exon 1 fibrils implicated in Huntington disease. [PDF]

Nat Commun
Bagherpoor Helabad M, Matlahov I, Kumar R, Daldrop JO, Jain G, Weingarth M, van der Wel PCA, Miettinen MS.   +7 more
europepmc   +1 more source

Hypocretin and Melanin‐Concentrating Hormone in Patients with Huntington Disease

, 2008
Ahmad Aziz, Rolf Fronczek, Marion L. C. Maat–Schieman, Unga A. Unmehopa, Freek W. C. Roelandse, Sebastiaan Overeem, Sjoerd G. van Duinen, Gert Jan Lammers, Dick F. Swaab, Raymund A.C. Roos   +9 more
openalex   +2 more sources

Neurocognitive signs in prodromal Huntington disease. [PDF]

, 2010
Julie C. Stout, Jane S. Paulsen, Sarah Queller, Andrea C. Solomon, Kathryn B. Whitlock, James C. Campbell, Noelle E. Carlozzi, Karen Duff, Leigh J. Beglinger, Douglas R. Langbehn, Hans J. Johnson, Kevin Biglan, Elizabeth Aylward   +12 more
openalex   +1 more source